Cargando…

Host-Directed Therapies for Tuberculosis

Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Eui-Kwon, Lee, Hyo-Ji, Jung, Yu-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697779/
https://www.ncbi.nlm.nih.gov/pubmed/36365041
http://dx.doi.org/10.3390/pathogens11111291
_version_ 1784838652705112064
author Jeong, Eui-Kwon
Lee, Hyo-Ji
Jung, Yu-Jin
author_facet Jeong, Eui-Kwon
Lee, Hyo-Ji
Jung, Yu-Jin
author_sort Jeong, Eui-Kwon
collection PubMed
description Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action.
format Online
Article
Text
id pubmed-9697779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96977792022-11-26 Host-Directed Therapies for Tuberculosis Jeong, Eui-Kwon Lee, Hyo-Ji Jung, Yu-Jin Pathogens Review Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action. MDPI 2022-11-03 /pmc/articles/PMC9697779/ /pubmed/36365041 http://dx.doi.org/10.3390/pathogens11111291 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jeong, Eui-Kwon
Lee, Hyo-Ji
Jung, Yu-Jin
Host-Directed Therapies for Tuberculosis
title Host-Directed Therapies for Tuberculosis
title_full Host-Directed Therapies for Tuberculosis
title_fullStr Host-Directed Therapies for Tuberculosis
title_full_unstemmed Host-Directed Therapies for Tuberculosis
title_short Host-Directed Therapies for Tuberculosis
title_sort host-directed therapies for tuberculosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697779/
https://www.ncbi.nlm.nih.gov/pubmed/36365041
http://dx.doi.org/10.3390/pathogens11111291
work_keys_str_mv AT jeongeuikwon hostdirectedtherapiesfortuberculosis
AT leehyoji hostdirectedtherapiesfortuberculosis
AT jungyujin hostdirectedtherapiesfortuberculosis